Clinical Trials Browser

Phase 1 × Completed × trametinib × Clear all

NCT03501368 2026-02-27

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Phase 1 Completed

Melanoma

NCT05668585 2025-11-21

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Phase 1 Completed

Melanoma

NCT05440942 2025-06-05

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT03299088 2025-05-21

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Phase 1 Completed

15 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT02070549 2025-02-13

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Phase 1 Completed

Neoplasm Metastasis

NCT03026517 2025-01-23

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1 Completed

Melanoma

NCT03434262 2024-05-31

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Phase 1 Completed

Choroid Plexus Carcinoma, Microphthalmia, Isolated, with Coloboma 5, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Lymphoma, Follicular, Medulloblastoma, Meningioma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Oligodendroglioma, Pinealoma, Recurrence, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT03317119 2024-04-08

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03516214 2024-02-15

EATON

Phase 1 Completed

Bronchial Neoplasms

NCT01740648 2023-09-18

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Phase 1 Completed

Gastrointestinal

Rectal Neoplasms

NCT03714958 2023-09-13

TRAHD

Phase 1 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02705963 2022-02-09

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT02292173 2021-06-10

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

Phase 1 Completed

Gastrointestinal

Digestive System Diseases, Liver Diseases, Liver Neoplasms

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Phase 1 Completed

Melanoma, Neoplasms

NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Phase 1 Completed

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01935973 2020-10-14

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 1 Completed

Endometrial Adenocarcinoma

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasmThoracic

Mesothelioma, Neoplasms

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

NCT01231594 2019-03-22

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Phase 1 Completed

Neoplasms

NCT02016729 2019-02-27

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01438554 2018-08-29

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Phase 1 Completed

GastrointestinalHead & NeckSarcoma

Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma

NCT02065063 2018-06-01

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Phase 1 Completed

Melanoma, Neoplasms

NCT02138292 2018-05-15

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

Phase 1 Completed

Melanoma

NCT01767454 2017-11-14

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Phase 1 Completed

Melanoma

NCT00687622 2017-11-13

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Phase 1 Completed

Melanoma, Neoplasms

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Phase 1 Completed

BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

Neoplasms

NCT01324258 2017-11-13

Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors

Phase 1 Completed

GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT01371487 2017-11-13

GSK1120212 Food-effect Study

Phase 1 Completed

Neoplasms

NCT01387204 2017-11-13

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

Phase 1 Completed

Neoplasms

NCT01416337 2017-11-13

Absolute Bioavialability of GSK1120212

Phase 1 Completed

Neoplasms

NCT01428427 2017-11-13

Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

Phase 1 Completed

Other hematologic neoplasm

Leukemia

NCT01476137 2017-11-13

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Phase 1 Completed

Multiple Myeloma, Neoplasms

NCT01647659 2017-11-13

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

Phase 1 Completed

Neoplasms

NCT01658553 2017-11-13

A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212

Phase 1 Completed

Neoplasms

NCT00955773 2017-11-09

Cancer

Phase 1 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

Phase 1 Completed

Advanced Cancer